Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice.
about
Sanfilippo syndrome: causes, consequences, and treatmentsFemale mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field testHematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activationGenistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic diseaseNeuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIBEffects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseasesDifferential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids.Adverse Effects of Genistein in a Mucopolysaccharidosis Type I Mouse ModelSynthetic genistein derivatives as modulators of glycosaminoglycan storage.A genetic model of substrate reduction therapy for mucopolysaccharidosis.The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.Residual N-acetyl-α-glucosaminidase activity in fibroblasts correlates with disease severity in patients with mucopolysaccharidosis type IIIBFactors and processes modulating phenotypes in neuronopathic lysosomal storage diseases.Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality.Gene expression-targeted isoflavone therapy.Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.Treatment options for lysosomal storage disorders: developing insights.Current and potential therapeutic strategies for mucopolysaccharidoses.Nanotechnology applied to treatment of mucopolysaccharidoses.Drug-Mediated Regulation of Glycosaminoglycan Biosynthesis.Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice.Coutinho et al. Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. Int. J. Mol. Sci. 2016, 17, 1065.Hyperactive behaviour in the mouse model of mucopolysaccharidosis IIIB in the open field and home cage environments.How close are we to therapies for Sanfilippo disease?Genistein supplementation in patients affected by Sanfilippo disease.Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model.Hyperactivity, unexplained speech delay, and coarse facies--is it Sanfilippo syndrome?
P2860
Q26773200-B2CF22A6-3A7D-4090-8FEF-DF0585099FC9Q27317299-B2E2794F-B49F-4A6C-9281-BA9D7510B264Q30524212-0249FB1E-E759-42DC-8354-391C61CDC7D5Q33761283-AF931738-74FB-4A5A-98C2-1996E9D4B860Q33769790-8E28E58D-758D-45EE-AD82-1C0ACFB5A0A9Q34256752-C190EE64-8422-4360-AD67-A62B9D5BDF33Q34626878-A132FF77-C3FC-41EF-97E6-5A53B8E902D7Q34714510-E8EABA52-CEFF-45B2-8707-4EEE7771A529Q34757062-F87F68FA-9943-4795-8A37-7D5BAB0CF1CDQ35206289-67FA7F9D-D8D8-463E-93C1-07058506C088Q35795405-C0EC28CD-9625-440B-8D47-112A7E4FE9EDQ36232973-8E993667-07BA-46C6-804C-DFFBE6483A84Q36332885-B407D724-D158-424B-A70E-F7D8DBF75972Q36433464-4367BAA5-EECB-4B50-B05D-A76D0B783D87Q36853478-514F3555-CA8C-4334-9F53-B4F290242FB3Q37595934-BC132CE5-09BF-401D-9C30-9B9211345390Q37876354-DF6C41D7-5E24-4C6E-A4A9-2718F4DD2713Q37987877-CD5C5A1C-0A7E-49AA-AA20-14382AEE3DB9Q38040710-04360C34-754E-4E5C-B642-9CB503D8EC62Q38046227-FDE7B7FC-D79A-4BD0-8543-68DAF26042CAQ38194635-3790D65F-6141-469A-9A30-DA3E872E1D63Q38850942-4471DCF5-7584-4410-9CF6-1AD2A03BBBBBQ39060517-108D35A4-E8E9-4E41-92D1-F1F17C8A7A95Q41969965-1E3CCF2E-7B31-4551-87D6-FCFE26B731BDQ42323200-E5DF9006-8CE0-434E-BB14-6D5427A89C62Q42603418-30D80132-7E3C-43CC-A52C-889E10C6182FQ45872078-057618EF-D552-4160-8BB8-4A9240CD980AQ48674391-7708DD58-3A0E-48DA-BF51-9B2E1ACFFD23Q50050416-125A2C3E-7023-4B2A-91BC-3A7ABBCF3F54Q50739346-A693E36C-30D3-4C2A-97C5-3C1E0D42D49D
P2860
Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@ast
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@en
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@nl
type
label
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@ast
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@en
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@nl
prefLabel
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@ast
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@en
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@nl
P2093
P50
P1476
Genistein reduces lysosomal st ...... mucopolysaccharide IIIB mice.
@en
P2093
Brian W Bigger
Fiona L Wilkinson
H Angharad O'Leary
J Ed Wraith
Kia J Langford-Smith
William Bennett
P304
P356
10.1016/J.YMGME.2009.06.013
P577
2009-06-27T00:00:00Z